|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Core Oncology, a developer of specialized medical products and an affiliate of Compass Capital. |
|---|---|
| Transferring Party | Mills Biopharmaceuticals, LLC, the brachytherapy division of Coloplast A/S, the third largest domestic supplier of Iodine 125 and Palladium Pd-103 seeds for low dose prostate brachytherapy treatment. |
| Sector | Biopharmaceuticals |
| Date | June 12, 2007 |
| Analysis Strengthens Core's position in the growing prostate brachytherapy market and adds critical mass to justify the deployment of resources to build sales domestically and internationally. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |